Dimensional Fund Advisors LP Has $23.04 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Dimensional Fund Advisors LP grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 36.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company's stock after buying an additional 528,962 shares during the quarter. Dimensional Fund Advisors LP owned about 1.94% of Intellia Therapeutics worth $23,042,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of NTLA. Sterling Capital Management LLC boosted its position in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $43,000. Jones Financial Companies Lllp increased its holdings in Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after acquiring an additional 2,280 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after acquiring an additional 2,299 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on NTLA shares. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Citigroup cut their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday. HC Wainwright initiated coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a "buy" rating and a $30.00 price target for the company. Finally, Oppenheimer reduced their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $36.90.

Intellia Therapeutics Trading Up 5.8%

NASDAQ NTLA traded up $0.47 during trading hours on Monday, reaching $8.59. 755,795 shares of the company traded hands, compared to its average volume of 2,471,333. The stock has a market capitalization of $889.47 million, a PE ratio of -1.61 and a beta of 2.33. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The company has a 50 day moving average of $8.13 and a two-hundred day moving average of $10.97.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. The business's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.12) earnings per share. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.